Kamada (KMDA) Capital Expenditures Growth (3y) (2015 - 2026)
Powered by 
Analysis
Kamada (KMDA) Capital Expenditures Growth (3y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 23.70% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 0.24% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 23.48% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 63.07% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -45.93% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 29.63% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -16.79% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | -26.94% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -26.94% |
| Mar 31, 2026 | 4.50% |
| Dec 31, 2025 | -41.62% |
| Sep 30, 2025 | -30.47% |
| Jun 30, 2025 | -43.75% |
| Mar 31, 2025 | -41.97% |
| Dec 31, 2024 | -57.81% |
| Sep 30, 2024 | -11.73% |
| Jun 30, 2024 | -31.23% |
| Mar 31, 2024 | -173.57% |
| Dec 31, 2023 | 2.29% |
| Sep 30, 2023 | -5.53% |
| Jun 30, 2023 | -0.82% |
| Mar 31, 2023 | -7.63% |
| Dec 31, 2022 | -6.36% |
| Sep 30, 2022 | -30.27% |
| Jun 30, 2022 | -14.39% |
| Mar 31, 2022 | -19.06% |
| Dec 31, 2021 | 4.38% |
| Sep 30, 2021 | -41.81% |